Bepirovirsen shows 19% functional cure rate in hepatitis B trials

On September 24, 2026, GSK announced significant results from its phase 3 B-Well trial, which evaluated the efficacy of bepirovirsen in treating adults with chronic hepatitis B. The trial demonstrated a 19% functional cure rate, a notable improvement compared to the standard care treatment, which reported a 0% functional cure rate. A functional cure is defined as achieving undetectable levels of HBV DNA and HBsAg for at least 24 weeks after discontinuing treatment. This outcome marks a promising advancement in the treatment options available for chronic hepatitis B, a condition that affects millions worldwide.

The B-Well trial was conducted across 29 countries and included over 1,800 participants, highlighting the global reach and significance of the study. Chronic hepatitis B poses a major public health challenge, often leading to serious liver complications, including cirrhosis and liver cancer. Before this trial, treatment options were limited, and achieving a functional cure was rare. The successful results from bepirovirsen showcase the potential for innovative therapies in managing chronic viral infections.

Implementation of the B-Well trial involved collaboration among various stakeholders, including healthcare providers, researchers, and participants. The robust design of the trial allowed for comprehensive data collection and analysis, contributing to the credibility of the findings. Bepirovirsen, an antisense oligonucleotide, represents a novel approach to hepatitis B treatment, focusing on targeting the virus's genetic material to inhibit its replication.

The implications of the trial results extend beyond individual patient outcomes. The successful demonstration of a functional cure with bepirovirsen could reshape the landscape of hepatitis B treatment, potentially leading to increased research and investment in similar therapies. Moreover, the availability of effective treatments can significantly reduce the burden on healthcare systems and improve the quality of life for those affected by chronic hepatitis B.

Looking forward, GSK is likely to pursue further studies and regulatory approvals for bepirovirsen, aiming to make this promising treatment widely accessible to patients. The success of the B-Well trial not only highlights the potential of bepirovirsen but also underscores the importance of continued research in the field of antiviral therapies. As the global health community seeks effective solutions for chronic diseases, the advancements represented by bepirovirsen may pave the way for future breakthroughs in hepatitis B management.